drop glp 1 the wellness company UVM Health cutting GLP-1 weight-loss drug coverage for employees What is GLP-1? Learning more
Description
Pharmacologic therapies, while more broadly accessible and less invasive, typically yield more modest reductions in visceral adiposity
The studies were a setback for the optimistic view that semaglutide and other drugs used in obesity and diabetes treatment could help prevent a number of brain diseases.
California lawmakers are moving to cut Medicaid coverage for some expensive weight-loss drugs, such as Novo Nordisks Wegovy and Eli Lillys Zepbound, in a bid to reduce the states $12 billion budget deficit.
Still Unsure
We do not promise specific timelines or outcomes
